Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PCV 20

Phase 3Biologic

PCV 20 is one of 12 biologic programs targeting Chickenpox. It is currently in Phase 3.

1

Indications

6

Total Trials

4

Active Trials

11

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChickenpoxRecruiting

ChickenpoxPhase 3

Recruiting

Competition

Competitive Landscape

11 competitors in Chickenpox

#DrugCompanyPhaseTrials

Zovirax

BBp Consulting, Inc

Marketed Paracetamol

Hepatitis a Vaccine

Investigational Cancer Drug

Vaxneuvance

MMR-Vaccine

Candidate Varicella Vaccine

PCV 20

YF-Vax

Valtrex

GGlaxo Dba Glaxosmithkline

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Chickenpox

NCT06693895

Q1 2027

Phase 3Recruiting

Chickenpox

NCT06855160

Q2 2027

Phase 3Recruiting

Chickenpox

NCT06806137

Phase 3Recruiting

Chickenpox

NCT06740630

Clinical

Trials by Indication[1]

Chickenpox4 trials

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06740630·1,840 enrolled

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06806137·600 enrolled

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06693895·750 enrolled

Show 1 more trial

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Recruiting· GSK logo

GSK·Phase 3·NCT06855160·900 enrolled

Vaccine2 trials

Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Completed·IInventprise Inc.·Phase 1·NCT05540028·65 enrolled

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Completed·IInventprise Inc.·Phase 2·NCT06077656·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for PCV 20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PCV 20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PCV 20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GSK

Related News